Angelo DeMarzo, M.D., PhD

Associate Director of Cancer Research Pathology, SKCCC
Professor of Pathology, Oncology, Urology

Johns Hopkins Medicine
Department of Pathology The Johns Hopkins University School of Medicine Bunting Blaustein Cancer Research Bldg, Rm. 153 1650 Orleans Street Baltimore, MD 21205 Lab Web Site:

Office: (410) 614-5686


Fax: (410) 502-9817

De Marzo Lab Overview

Our laboratory is focused on developing new insights into the molecular pathobiology of prostate cancer. For example, we are interested in determining the cell type of origin and the molecular mechanisms involved in neoplastic transformation in the prostate. We also perform translational research in which we interrogate biomarker expression in human prostate tissues, where such biomarkers might aid the pathologist in making a diagnosis on challenging biopsy cases, help to predict outcome, help determine whether a given pathway alteration is present, or help to determine whether a drug has hit its target.

We are also involved in tissue banking, as well as, in tissue microarray technology and tissue microarray software and database design, and image analysis of tissue microarrays. Our laboratory works very closely with the physically adjacent labs of William G. Nelson MD PhD, Srinivasan Yegnasubramanian MD PhD and Karen Sfanos PhD in a number of related research areas. We also collaborate extensively with Alan K. Meeker PhD, and Elizabeth Platz ScD PSD, from the Johns Hopkins Bloomberg School of Public Health, and a range of other investigators, both within and outside of Johns Hopkins.


1987 B.A. University of Colorado at Boulder, Molecular, Cellular & Developmental Biology and Psychology
1994 M.D. Ph.D. University of Colorado Health Sciences Center, Denver CO (PhD in Experimental Pathology with mentor Dean P. Edwards PhD.
1994-1995 Internship in Anatomic Pathology The Johns Hopkins University School of Medicine
1995-1996 Resident in Anatomic Pathology The Johns Hopkins University School of Medicine
1996-1997 Chief Resident in Pathology The Johns Hopkins University School of Medicine
1997-1998 Research and Clinical Fellow in Genitourinary Pathology The Brady Urological Institute, The Johns Hopkins University School of Medicine, Donald S. Coffey Research Mentor

Licensure & Certifications

  • National Board of Medical Examiners
  • National Board of Medical Examiners
  • United States Medical Licensing Exam
  • Maryland Board of Physician Quality Assurance
  • Diplomat, American Board of Pathology, Anatomic Pathology


Free Access to abstracts at PubMed


  1. Miller, G.J., De Marzo AM Ultrastructural localization of alkaline phosphatase and matrix vesicles in the swarm rat chondrosarcoma: their role in cartilage calcification. Bone, 9:235-241, 1988.

  2. Christensen, K., Estes, P. A., Oñate, S. A., Beck, C. A., De Marzo AM, Altmann, M., Lieberman, B. A., St-John, J., Nordeen S. K. and Edwards, D. P. Characterization and functional properties of the A and B forms of human progesterone receptors synthesized in a baculovirus system. Mol Endocrinol, 5:1755-1770, 1991.

  3. De Marzo AM, Beck, C. A., Oñate, S. A. and Edwards, D. P. Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein. Proc. Natl. Acad. Sci. USA, 88:72-76, 1991. 1

  4. Edwards, D. P., Estes, P. A., Oñate, S. A., Beck, C. A., De Marzo AM and Nordeen, S. K. Mechanisms controlling steroid receptor binding to specific DNA sequences. Breast Epithelial Antigens, Plenum Press (Ed. R. L. Ceriami) 1991.

  5. Edwards, D. P., De Marzo AM, Oñate, S. A., Beck, C. A., Estes, P. A. and Nordeen, S. K. Mechanisms controlling steroid receptor binding to specific DNA sequences. Steroids 56:271-278, 1991.

  6. De Marzo AM, Oñate, S. A., Nordeen, S. K. and Edwards, D. P. Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor. Biochemistry, 31: 10491-10501, 1992.

  7. Edwards, D.P., Altman, M., De Marzo AM and Beck, C.A. Progesterone receptor and the mechanism of action of progesterone antagonists. J. Steroid Biochem and Molecular Bio, 53: 449-, 1995.

  8. Ferreira, R., Moon, B., Humphries, J., Sussman, A., Saltz, J., Miller R., and De Marzo AM The Virtual Microscope. Proc. AMIA Annu. Fall. Symp. 449-53, 1997.

  9. Afework, A., Beynon, M.D., Bustamante, F., Cho, S., De Marzo AM, Ferreira, R., Miller, R., Silberman, M., Saltz, J., Sussman, A., Tsang, H. Digital dynamic telepathology--the Virtual Microscope. Proc AMIA Symp. 912-916, 1998.

  10. De Marzo AM, Bradshaw, C., Sauvageot, J., Epstein, J.I., and Miller, G.J. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate, 34: 162-168, 1998.

  11. De Marzo AM, Nelson, W.G., Meeker, A.K., and Coffey, D.S. Stem cell features of benign and malignant prostate epithelial cells. J. Urol., 160(6 Pt 2):2381-2392, 1998. 12. Halachmi, S. De Marzo AM, Epstein, J.I., and Schoenberg, M. Extensive squamous cell carcinoma in situ masking deeply invasive disease. J Urol. 159:203, 1998.

  12. De Marzo AM, Meeker, A.K., Epstein, J.I., and Coffey, D.S. Prostate stem cell compartments: Expression of the cell cycle inhibitor P27Kip1 in normal, hyperplastic, and cancer cells. Am. J. Pathol., 153:911-917, 1998.

  13. Halachmi, S. De Marzo AM, Epstein, J.I., and Schoenberg, M. Extensive squamous cell carcinoma in situ masking deeply invasive disease. J Urol. 159:203, 1998.

  14. De Marzo AM, Meeker, A.K., Epstein, J.I., and Coffey, D.S. Prostate stem cell compartments: Expression of the cell cycle inhibitor P27Kip1 in normal, hyperplastic, and cancer cells. Am. J. Pathol., 153:911-917, 1998.

  15. De Marzo AM, Chan-Tack, K., Knudson, B., and Epstein, J.I. E-cadherin in routinely processed radical prostatectomy specimens. Urology, 53: 707-713, 1999.

  16. De Marzo AM, Marchi, V.L., Yang, E., Veeraswamy, R., Lin, X., and Nelson, W.G. Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. Cancer Res., 59:3855-3860, 1999.

  17. Simons, J.W., Mikhak, B., Chang, J-F. , De Marzo AM.M., Carducci, M.A., Lim, M., Weber, C.B. Baccala, A.A., Goemann, M.A., Clift, S.M., Ando, D.G., Livitsky, H.I., Cohen, L.K., Sanda, M.G., Mulligan R.C., Partin, A.W., Carter, H.B., Piantadosi, S., Marshall, F.F., and Nelson, W.G. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete GM-CSF using ex-vivo gene transfer. Cancer Res., 59:5160-5168, 1999.

  18. De Marzo AM, Marchi, V.L., Epstein, J.I., and Nelson, W.G. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol., 155: 1985-1992, 1999.

  19. Zhong H., De Marzo AM.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res., 59:5830-5835, 1999.

  20. De Marzo AM, Coffey, D.S., and Nelson, W.G. New concepts in tissue specificity of prostate cancer and benign prostatic hyperplasia. Urology, 53 (Suppl 3A):29-39, 1999.

  21. Tchou J.C., Lin X., Freije D., Isaacs W.B., Brooks J.D., Rashid A., De Marzo AM.M., Kanai Y., Hirohashi S., Nelson W.G. GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas. Int. J. Oncol., 16:663-676, 2000.

  22. Halachmi, S., De Marzo2, A.M., Chow, N., Halachmi, N., Smith, A.E., Linn, J.F., Epstein, J.I., Schoenberg, M., and Sidransky, D. Genetic alterations in bladder carcinosarcoma: evidence of a common clonal origin. Eur Urol., 37: 350-357, 2000.

  23. Nelson, W.G., Simons, J.W., Mikhak, B., Chang, J.F., De Marzo AM, Carducci, M.A., Kim, M., Weber, C.E., Baccala, A.A., Goemann, M.A., Clift, S.M., Ando, D.G., Levitsky, H.I., Cohen, L.K., Sanda, M.G., Mulligan, R.C., Partin, A.W., Carter, H., Piantadosi, S., Marshall, F.F. Cancer cells engineered to secrete granulocyte-macrophage colony stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol 2000;46 Suppl:S67-72.

  24. Weeraratna A.T., Arnold J.T., George D.J., De Marzo AM.M., and Isaacs J.T. Rational basis for Trk inhibition therapy for prostate cancer. Prostate, 45:140-8, 2000.

  25. David-Beabes, G.L., Overman, M.J., Petrofski, J.A., Campbell, P.A., De Marzo AM, Nelson, WG. Doxorubicin-resistant variants of human prostate cancer cell DU 145, PC3 and TSU-PR1: characterization of biochemical determinants of antineoplastic sensitivity. Int. J. Oncol., 17:1077-1086, 2000.

  26. Putzi, M. P., and De Marzo AM Morphological transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology, 56:828-832, 2000.

  27. Nelson, C.P., Kidd, L.C., Sauvageot, J., Isaacs, W.B., De Marzo AM, Groopman, J.D., Nelson, W.G., Kensler, T.W. Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res., 61:103-109, 2001.

  28. Nelson, W.G., De Marzo AM, DeWeese, T.L. The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. Urology, 57(4 Suppl 1):39-45, 2001.

  29. Parsons, J.K., Nelson, C.P., Gage, W.R., Nelson, W.G., De Marzo AM GSTA1 expression in normal, pre-neoplastic, and neoplastic human prostate tissue. The Prostate, 49:30-37, 2001.

  30. Parsons, J.K., Gage, W.R., Nelson, W.G., De Marzo AM p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology, 58:619-624, 2001.

  31. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo A.M., Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61:7464-72, 2001.

  32. Manley S., Mucci N.R., De Marzo AM.M., Rubin M.A. Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome : the prostate specialized program of research excellence model. Am. J. Pathol.159:837-43, 2001.

  33. Zha, S., Gage, W. R., Sauvageot, J., Saria, E. A., Putzi, M. J., Ewing, C. M., Faith, D. A., Nelson, W. G., De Marzo3, A. M., and Isaacs, W. B. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma, Cancer Res. 61: 8617-23, 2001.

  34. Lin, X., Asgari, K., Putzi, M. J., Gage, W. R., Yu, X., Cornblatt, B. S., Kumar, A., Piantadosi, S., DeWeese, T. L., De Marzo, A. M., and Nelson, W. G. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi- class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res., 61: 8611-6, 2001.

  35. Lin, X., Tascilar, M., Lee, W.H., Vles, W.J., Lee, B.H., Veeraswamy, R., Asgari, K., Freije, D., van Rees, B., Gage, W.R., Bova, G.S., Isaacs, W.B., Brooks, J.D., DeWeese, T.L., De Marzo AM, Nelson, W.G. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am. J. Pathol. 159:1815-1826, 2001.

  36. Nelson, W.G., De Marzo AM, DeWeese, T.L. The molecular pathogenesis of prostate cancer: focus on the earliest steps. Eur Urol 39(suppl 4):8-11, 2001.

  37. De Marzo AM.M., Putzi, M.P. and Nelson, W.G. New concepts in the pathology of prostate epithelial carcinogenesis. Urology, 57 (Suppl 4A):103-114, 2001.

  38. Nelson, W. G., De Marzo, A. M., Deweese, T. L., Lin, X., Brooks, J. D., Putzi, M. J., Nelson, C. P., Groopman, J. D., and Kensler, T. W. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention, Ann N Y Acad Sci. 952: 135-144, 2001.

  39. Putzi, M.P. and De Marzo AM Prostate pathology: histologic and molecular perspectives. Hematology/Oncology Clinics of North America.3:407-421, 2001.

  40. De Marzo AM In memoriam: Gary J. Miller, MD, PhD. Prostate 48:128-130, 2001.

  41. Carpten, J., Nupponen, N., Isaacs, S., Sood, R., Robbins, C., Xu, J., Faruque, M., Moses, T., Ewing, C., Gillanders, E., Hu, P., Bujnovszky, P., Makalowska, I., Baffoe-Bonnie, A., Faith, D., Smith, J., Stephan, D., Wiley, K., Brownstein, M., Gildea, D., Kelly, B., Jenkins, R., Hostetter, G., Matikainen, M., Schleutker, J., Klinger, K., Connors, T., Xiang, Y., Wang, Z., De Marzo, A., Papadopoulos, N., Kallioniemi, O.P., Burk, R., Meyers, D., Gronberg, H., Meltzer, P., Silverman, R., Bailey-Wilson, J., Walsh, P., Isaacs, W., Trent, J. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet., 30:181-184, 2002.

  42. Meeker, A. K., Gage, W. R., Hicks, J. L., Simon, I., Coffman, J. R., Platz, E. A., March, G. E., and De Marzo, A. M. Telomere length assessment in human archival tissues: combined telomere fluorescent in situ hybridization and immunostaining, Am J Pathol. 160:1259-1268, 2002.

  43. Luo, J., Gage, W. R., Hicks, J. L., Wanders, R. J., Trent, J. M., Isaacs, W. B., and De Marzo, A. M. Overexpression of alpha methyl acyl-coa racemase (AMACR) in prostate cancer analyzed by cDNA microarrays and high density tissue microarrays. Cancer Res., 62:2220-2226, 2002.

  44. De Marzo AM.M., Fedor H., Gage W.R., Rubin, M.A. Inadequate formalin fixation reduces reliability of p27Kip1 immunohistochemical staining: probing optimal fixation time using high-density tissue microarrays. Human Path, 33:756-60, 2002.

  45. Xu J., Zheng S.L., Komiya, A., Mychaleckyj, J., Isaacs, S.D., Hu, J.J., Sterling, D., Lange, E.M., Hawkins, G.A., Turner, A., Ewing, C.M., Faith, D.A., Johnson, J.R., Suzuki, H., Bujnovszky, P., Wiley, K.E., De Marzo AM, Bova, G.S., Chang, B., Hall, M.C., McCullough, D.L., Partin, A.W., Kassabian, V.S., Carpten, J.D., Baily-Wilson, J.E., Trent, J.M., Ohar, J., Bleecker, E.R., Walsh, P.C., Isaacs, W.B., Meyers, D.A. Germline mutations of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk in Caucasian and African American men. Nat Genet., 32:321-5, 2002.

  46. Meeker, A.K., Hicks, J.L., Platz, E.A., March, G.E., Bennett, C.J., Delannoy, M.J., De Marzo AM Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res., 62:6405-9, 2002.

  47. van Heek, N.T., Meeker, A.K., Kern, S.E., Yeo, C.J., Lillemoe, K.D., Cameron, J.L., Offerhaus, G.J., Hicks, J.L., Wilentz, R.E., Goggins, M.G., De Marzo AM, Hruban, R.H., Maitra, A. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am. J. Pathol., 161:1541-7, 2002.

  48. Sachs, M.D., Rauen, K.A., Ramamurthy, M., Dodson, J.L., De Marzo AM, Putzi, M.J., Schoenberg, M.P., Rodriguez, R., Integrin alpha (v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology, 60:531-6, 2002.

  49. Nelson, W.G., DeWeese, T.L., De Marzo AM, The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev., 21:3-16, 2002.

  50. Isaacs, W.B., De Marzo AM, and Nelson, W.G. Focus on prostate cancer. Cancer Cell, 2:113, 2002.

  51. Heath, E.I., DeWeese, T.L., Partin, A.W., De Marzo AM, Groopman, J.D., Nelson, W.G., Piantadosi, S.A., Lieberman, R, Carducci, M.A.The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate. Clin Prostate Cancer. 1:182-7, 2002.

  52. Nelson, W.G., DeWeese, T.L., De Marzo AM, Brooks,J.D. Prostate cancer prevention. Prostate Cancer, Lippincott Williams & Wilkins (Ed. P.W. Kantoff, P. Carroll, and A.D'Amico) 2002, pp103-114.

  53. Collis, S.J., Ketner G.W., Hicks J.L., Nelson W.G., De Marzo AM, and Deweese T.L. Expression of the DNA-PK binding protein E4-34K fails to confer radiation sensitivity to mammalian cells. Int J Radiat Biol., 79:53-60, 2003.

  54. Gonzalgo, M.L., de Lacerda D.A., De Marzo AM, and Chan D.Y. Persistent purulent drainage from the glans penis: atypical presentation of pyoderma gangrenosum. J. Urol., 169:1793-4, 2003.

  55. De Marzo AM, Nelson, W.G., Isaacs, W.B., and Epstein, J.I. Pathological and molecular aspects of prostate cancer. Lancet, 361:955-64, 2003.

  56. Van Leenders, G.J., Gage, W.R., Hicks J.L., Van Balken, B., Aalders, T.W., Schalken, J.A., and De Marzo AM Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol., 162:1529-37, 2003.

  57. Nelson, W.G., De Marzo AM, and Isaacs, W.B. Mechanisms of disease. The molecular pathogenesis of prostate cancer: a new role for inflammation? New Eng. J. Med., 349:366-81, 2003.

  58. Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab. 88:2972-82, 2003.

  59. Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, De Marzo AM, Epstein JI. Alpha-Methylacyl-CoA Racemase: A Variably Sensitive Immunohistochemical Marker for the Diagnosis of Small Prostate Cancer Foci on Needle Biopsy. Am J Surg Pathol. 8:1128-33. 2003.

  60. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, and De Marzo AM. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol., 163:923-933, 2003.

  61. Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo AM, Cameron JL, Yeo CJ, Hruban RH. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol. 9:902-12, 2003.

  62. Volmar KE, Chan TY, De Marzo AM, and Epstein JI. Am J Surg Pathol.Florid von Brunn nests mimicking urothelial carcinoma: a morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma. 9:1243-52, 2003.

  63. Zha S, Ferdinandusse S, Denis S, Wanders RJ, Ewing CM, Luo J, De Marzo AM, Isaacs WB. Alpha-methylacyl-coa racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res. 63:7365-7376, 2003.

  64. Meeker AK and De Marzo AM. Recent advances in telomere biology: implications for human cancer. Curr Opin Oncol. 16:32-8. 2004.

  65. Platz E and De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol. 171:S36-S40, 2004.

  66. Lapointe J, Li C, Higgins JP, Van De Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, and Pollack JR. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA. 101:811-6, 2004.

  67. Rubin MA and De Marzo AM. Molecular genetics of human prostate cancer. Mod Pathol. 17:380-388, 2004.

  68. Bachman KE, Blair BG, Brenner K, Bardelli A, Arena S, Zhou S, Hicks J, De Marzo AM, Argani P, Park BH. p21(WAF1/CIP1) Mediates the Growth Response to TGF-beta in Human Epithelial Cells. Cancer Biol Ther. 3:221-225, 2004.

  69. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI, Isaacs WB, Nelson WG. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem. 91:459-77, 2004.

  70. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem. 91:540-52, 2004.

  71. Platz EA, De Marzo AM, Giovannucci E. Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era. J Cell Biochem. 91:553-71, 2004.

  72. . Platz EA, De Marzo AM, Giovannucci E. Failure to detect prostate cancer in the PSA era: comments on N Engl J Med 2003. 349: 215-224 and N Engl J Med. 349: 335-342. 2003. Cancer Causes Control. 15 :91-4, 2004.

  73. Gonzalgo ML, Nakayama M, Lee SM, De Marzo AM, Nelson WG. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology. 63:414-8, 2004.

  74. Meeker AK, Hicks JL, Gabrielson E, Strauss WM, De Marzo AM, Argani P. Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am J Pathol. 164:925-35, 2004.

  75. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 64:1975-86, 2004.

  76. Bastian PJ, Nakayama M, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular marker in the carcinogenesis of prostate cancer. Urologe A. 43:573-9, 2004 (in german).

  77. David GL, Yegnasubramanian S, Kumar A, Marchi VL, De Marzo AM, Lin X, Nelson WG. MDR1 Promoter Hypermethylation in MCF-7 Human Breast Cancer Cell: Changes in Chromatin Structure Induced by Treatment with 5-Aza-Cytidine. Cancer Biol Ther. 3:e1-e9, 2004.

  78. Platz EA, De Marzo AM, Erlinger TP, Rifai N, Visvanathan K, Hoffman SC, Helzlsouer KJ. No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. Prostate. 59:393-400, 2004.

  79. . Zhong H, Semenza GL, Simons JW, De Marzo AM. Up-regulation of hypoxia-inducible factor 1 alpha is an early event in prostate carcinogenesis. Cancer Detect Prev. 28:88-93, 2004.

  80. Montgomery E, Argani P, Hicks JL, DeMarzo AM, Meeker AK. Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol. 164:1523-9, 2004.

  81. Meeker AK, Hicks JL, Iacobuzio-Donahue CA, Montgomery EA, Westra WH, Chan TY, Ronnett BM, De Marzo AM. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res. 10: 3317-26, 2004.

  82. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett, 215(1):1-20, 2004.

  83. Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB, Luo J, De Marzo AMM, Nelson WG, Pavlovich CP. Prostate cancer detection on urinalysis for [alpha] methylacyl coenzyme a racemase protein. J Urol. 172:1501-1503, 2004.

  84. Faith DA, Isaacs WB, Morgan JD, Fedor HL, Hicks JL, Mangold LA, Walsh PC, Partin AW, Platz EA, Luo J, De Marzo AM. Trefoil factor 3 overexpression in prostatic carcinoma: Prognostic importance using tissue microarrays. The Prostate, 61:215-, 2004.


Antibody to Human DNA Methyltransferase 1 (JHU Ref 4328)


  • 1987. American Medical Association (AMA) - member 1987-1994.
  • American Society of Clinical Pathologists - member since 1995.
  • College of American Pathologists - member since 1995.
  • Alpha Omega Alpha - elected 1993. American Urological Association - associate member since 1998.
  • American Association for Cancer Research - member since 2001.

Awards & Honors

1982-1987 Dean's List - Six Semesters at University of Colorado, Boulder.
1993 Elected to Alpha Omega Alpha (AOA) Society
1997-1998 Research and Clinical Fellowship, NIH Training Grant in Pathobiology of Cancer.
1998 Stowell-Orbison Award for Research by a Pathologist-In-Training, International Academy of Pathology.
1998 Mentored Clinician Scientist Development Award (K08), National Institutes of Health, National Cancer Institute.
1998 &1999 Harvey/Burroughs Wellcome Clinician Scientist Award, The Johns Hopkins Medical Institutions.
2000 Aegon Fellowship in Breast and Prostate Cancer Research
2002 Achievement Award in Scientific Session: TMAJ, A Johns Hopkins Set of Open Source Software Tools to Manage a Multi-Organ, Scalable, Secure, Multi-User Tissue MicroArray Database. 2002 Meeting: Advanceing Pathology Informatics, Imaging and the Internet, Pittsburgh. PA.